Cholestatic	cholestatic	O	O
jaundice	jaundice	O	S_disease
associated	associated	O	O
with	with	O	O
the	the	O	O
use	use	O	O
of	of	O	O
metformin	metformin	O	O
.	.	O	O

We	we	O	O
report	report	O	O
a	a	O	O
patient	patient	O	O
who	who	O	O
developed	developed	O	O
cholestatic	cholestatic	O	O
jaundice	jaundice	O	S_disease
shortly	shortly	O	O
after	after	O	O
initiation	initiation	O	O
of	of	O	O
treatment	treatment	O	O
with	with	O	O
metformin	metformin	O	O
hydrochloride	hydrochloride	O	O
.	.	O	O

Ultrasound	ultrasound	O	O
of	of	O	O
the	the	O	O
liver	liver	O	O
and	and	O	O
abdominal	abdominal	O	O
CT	ct	O	O
were	were	O	O
normal	normal	O	O
.	.	O	O

An	an	O	O
ERCP	ercp	O	O
showed	showed	O	O
normal	normal	O	O
biliary	biliary	O	O
anatomy	anatomy	O	O
.	.	O	O

A	a	O	O
percutaneous	percutaneous	O	O
liver	liver	O	O
biopsy	biopsy	O	O
was	was	O	O
obtained	obtained	O	O
showing	showing	O	O
marked	marked	O	O
cholestasis	cholestasis	O	S_disease
,	,	O	O
with	with	O	O
portal	portal	O	O
edema	edema	O	S_disease
,	,	O	O
ductular	ductular	O	O
proliferation	proliferation	O	O
,	,	O	O
and	and	O	O
acute	acute	O	O
inflammation	inflammation	O	S_disease
.	.	O	O

Metformin	metformin	O	O
hydrochloride	hydrochloride	O	O
was	was	O	O
discontinued	discontinued	O	O
,	,	O	O
and	and	O	O
the	the	O	O
patient	patient	O	O
's	's	O	O
jaundice	jaundice	O	S_disease
resolved	resolved	O	O
slowly	slowly	O	O
over	over	O	O
a	a	O	O
period	period	O	O
of	of	O	O
several	several	O	O
months	months	O	O
.	.	O	O

Given	given	O	O
the	the	O	O
onset	onset	O	O
of	of	O	O
his	his	O	O
jaundice	jaundice	O	S_disease
2	2	O	O
wk	wk	O	O
after	after	O	O
the	the	O	O
initiation	initiation	O	O
of	of	O	O
metformin	metformin	O	O
,	,	O	O
we	we	O	O
believe	believe	O	O
that	that	O	O
this	this	O	O
case	case	O	O
represents	represents	O	O
an	an	O	O
example	example	O	O
of	of	O	O
metformin-associated	metformin-associated	O	O
hepatotoxicity	hepatotoxicity	O	S_disease
,	,	O	O
the	the	O	O
first	first	O	O
such	such	O	O
case	case	O	O
reported	reported	O	O
.	.	O	O

